comparemela.com

Latest Breaking News On - Results from - Page 2 : comparemela.com

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

VANCOUVER, British Columbia, May 28, 2024 Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner clinical data in.

United statesBritish columbiaUnited kingdomJodi regtsJoe mcintoshIan mortimerExchange commissionClinical developmentSecurities exchangeAmerican society of clinical psychopharmacologyXenon pharmaceuticals incXenon corporate affairsXenon pharmaceuticals nasdaqXenon pharmaceuticalsAmerican societyClinical psychopharmacology

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 HUTCHMED Limited today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be.

Qing zhaiFeng wangUnited statesYang wangHong kongSheng liZhang zhenLu wangAtholl tweedieJunjie pengXing zhangXianjun yuShuiping tuLinhui zhuDongsheng zhangLiangjun zhu

HUTCHMED Highlights Presentations at the 2024 ASCO Annual

HUTCHMED Highlights Presentations at the 2024 ASCO Annual
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Sheng liYang wangUnited statesHong kongFeng wangZhang zhenLu wangQing zhaiJunjie pengCathy engWenhua liDongsheng zhangJianjun pengSusheng shiXiaohua wuAtholl tweedie

HUTCHMED Presentations at 2024 ASCO Annual Meeting | Company Announcement

Investegate announcements from HUTCHMED Presentations at 2024 ASCO Annual Meeting

Qing zhaiYang wangHong kongUnited statesZhang zhenFeng wangLu wangSheng liCathy engZhenyu linWenhua liAfei maAtholl tweedieWenbo wangBen atwell alex shawTanioss bekaii saab

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational.

Hong kongUnited statesOlmsted countyUnited kingdomChuck trianoJack coxTravis murdochPriya singhalMorgan warnersExchange commissionHead of development at biogenGoodwin procterBofa securities incDrug administrationCovington burlingHuman immunology biosciences inc

vimarsana © 2020. All Rights Reserved.